About this episode
It's hard to put a value on a human life. When you're well, perhaps you don't think about it. But if you're ill, getting access to the right drugs, whatever the cost, is a priority. But the NHS does not have a bottomless pit of money. And some medicines are judged too expensive to be freely available, so patients miss out on treatments that could save or extend their lives. There are usually two villains of the piece: The drugs companies for charging too much; the NHS for not stumping up the cash. In this edition, Evan Davis and guests explore how pharmaceutical companies price their drugs, the role of the NHS in deciding how much the medicines are worth and, in the case of generic or non-branded drugs, they'll ask whether competition is working properly to keep down the NHS medicines bill.
Guests: Erik Nordkamp, Managing Director, Pfizer UK
Carole Longson, Director of the Centre for Health Technology Evaluation at NICE, the National Institute for Health and Care Excellence
Warwick Smith, Director-General, British Generic Manufacturers Association
Producer: Sally Abrahams.
Get every episode summarized
Each time The Bottom Line publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
